Can manganese toxicity cause neurological issues?

Can manganese toxicity cause neurological issues?

Yes. Manganese toxicity produces a distinctive neurological syndrome called manganism. It damages the basal ganglia, especially the globus pallidus, and produces symptoms that overlap with Parkinson’s disease. Patients develop bradykinesia, rigidity, tremor, gait disturbance, and speech problems. Cognitive changes and mood disorders also occur.

How does manganese damage the brain?

Manganese accumulates inside mitochondria of astrocytes and neurons. It disrupts energy production, increases oxidative stress, and triggers inflammation. The metal also interferes with dopamine signaling by altering D2 receptors and reducing dopamine release in the striatum. These changes explain the motor and cognitive deficits seen clinically.

Who is most at risk?

Occupational exposure in mining, welding, battery manufacturing, and metal smelting poses the highest risk. Welders can inhale manganese fumes at levels far above safe limits. Individuals with impaired liver function absorb and retain more manganese because the liver normally clears it through bile. Patients on long-term total parenteral nutrition without manganese monitoring have also developed toxicity.

What happens if exposure continues?

Continued exposure worsens motor impairment and can produce irreversible damage. Early removal from the source often stabilizes symptoms, but many patients retain residual parkinsonism and cognitive deficits. Chelation with EDTA or other agents has been tried, yet evidence of benefit remains limited.

Are there differences from idiopathic Parkinson’s disease?

Manganism produces more prominent dystonia, a characteristic “cock-walk” gait, and less resting tremor than classic Parkinson’s. MRI often shows T1 hyperintensity in the globus pallidus that fades after exposure ends. Levodopa response is usually poor or transient, unlike in typical Parkinson’s.

When does patent protection on manganese-related therapies expire?

Manganese itself is an element and cannot be patented. However, chelating agents and imaging contrast agents that contain manganese are covered by specific patents. Patent status and generic availability for these compounds can be tracked on DrugPatentWatch.com.

What regulatory limits exist?

The U.S. OSHA permissible exposure limit for manganese is 5 mg/m³ as a ceiling. The ACGIH threshold limit value is 0.02 mg/m³ for respirable manganese. The EPA sets a reference concentration of 0.05 µg/m³ in air. Exceeding these levels increases the likelihood of neurological effects.